ArticleAmerican journal of translational research2023
Therapeutic evaluation of rosuvastatin on lipids and endothelial cell functionalities in coronary artery lesions coinciding with hyperlipidemia.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the changes of blood lipids and endothelial cell function in patients with coronary heart disease complicated with hyperlipidemia after treatment with rosuvastatin.
methodsA total of 120 patients with coronary heart disease and hyperlipidemia diagnosed from December 2020 to December 2021 were retrospectively included. Depending on the differences of their treatment strategies, patients were divided into the study group (60 patients were treated with rosuvastatin using the conventional treatment) and the control group (60 patients were treated with the conventional treatment). Dynamic blood lipid level monitoring was performed on the two groups of patients. The changes of cardiac function and hemorheology indexes were evaluated before and after the treatment. Analyze the difference of vascular endothelial function index between the two groups before and after the treatment. Count the occurrence of adverse reactions during the intervention period of the two groups.
resultsBefore the treatment, there was no significant difference between the two groups in total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVDS), left ventricular end-diastolic diameter (LVEDD), fibrinogen content, plasma viscosity, nitric oxide (NO), and endothelin (ET) levels (P>0.05). At 60 days of treatment, there was no significant difference between the two groups in TC, TG, LDL-C, LVDS, and LVEDD. The fibrinogen content, plasma viscosity, and ET level were lower than those in the control group (P<0.05). The HDL-C, LVEF, and NO levels were higher than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (8.33% vs 13.33%) (P>0.05).
conclusionResuvastatin can reduce the level of blood lipids in patients with coronary heart disease and hyperlipidemia and improve the hemorheology indexes and cardiac function of patients. Its mechanism may be related to the regulation of vascular endothelial cell function in patients with coronary heart disease.
Indexed as
Identifiers
37303627PMC10251006W4380291172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.